As the burgeoning field of cell therapy evolves, so do the practices around obtaining the raw biological material needed to create these life-changing treatments.
Shares in Cellectis shot up this morning after the French biotech revealed a wide-ranging alliance with AstraZeneca, which includes $245 million in near-term financial com
Bayer is backing up its move into the cell therapy category led by subsidiary BlueRock Therapeutics with a $250 million investment in a new manufacturing facility in Berke
An FDA advisory committee has voted by a huge margin that BrainStorm’s stem cell therapy for amyotrophic lateral sclerosis (ALS) – NurOwn – does not have enough data to su
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.